drugset / Trial / NCT07503444

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

NCT07503444

Phase 3 Not yet recruiting 200 enrolled UCB BIOSCIENCES, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to investigate the efficacy of fenfluramine hydrochloride (HCl) versus placebo in study participants with Rett syndrome (RTT).

Timeline

Start
2026-06-30
Primary completion
2028-08-01
Completion
2030-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenfluramine Small molecule Oral

Indications